Correlation Between Evolus and Alnylam Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Evolus and Alnylam Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Evolus and Alnylam Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Evolus Inc and Alnylam Pharmaceuticals, you can compare the effects of market volatilities on Evolus and Alnylam Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Evolus with a short position of Alnylam Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Evolus and Alnylam Pharmaceuticals.

Diversification Opportunities for Evolus and Alnylam Pharmaceuticals

0.0

Correlation Coefficient

Evolus  Alnylam Pharmaceuticals

Pay attention - limited upside

The 3 months correlation between Evolus and Alnylam is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Evolus Inc and Alnylam Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Alnylam Pharmaceuticals and Evolus is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Evolus Inc are associated (or correlated) with Alnylam Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Alnylam Pharmaceuticals has no effect on the direction of Evolus i.e., Evolus and Alnylam Pharmaceuticals go up and down completely randomly.

Pair Corralation between Evolus and Alnylam Pharmaceuticals

Given the investment horizon of 90 days Evolus Inc is expected to under-perform the Alnylam Pharmaceuticals. In addition to that, Evolus is 1.33 times more volatile than Alnylam Pharmaceuticals. It trades about -0.41 of its total potential returns per unit of risk. Alnylam Pharmaceuticals is currently generating about -0.22 per unit of volatility. If you would invest  15,333  in Alnylam Pharmaceuticals on February 1, 2024 and sell it today you would lose (938.00) from holding Alnylam Pharmaceuticals or give up 6.12% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Flat
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Evolus Inc  vs.  Alnylam Pharmaceuticals

Evolus Inc

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Evolus Inc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's essential indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Alnylam Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Alnylam Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in June 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Evolus and Alnylam Pharmaceuticals

The main advantage of trading using opposite Evolus and Alnylam Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Evolus position performs unexpectedly, Alnylam Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alnylam Pharmaceuticals will offset losses from the drop in Alnylam Pharmaceuticals' long position.

The idea behind Evolus Inc and Alnylam Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.